Taysha Gene Therapies, Inc. TSHA Other Working Capital
Other Working Capital at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s other working capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s other working capital?
- Taysha Gene Therapies, Inc. (TSHA) reported other working capital of -$27K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s other working capital changed year-over-year?
- Taysha Gene Therapies, Inc.'s other working capital decreased by 640.0% year-over-year, from $5K to -$27K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s other working capital?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s other working capital has grown at a -31.1% compound annual growth rate (CAGR), from -$906K to -$296K.
- What does other working capital mean?
- Net change in working capital items not separately classified — a residual balancing item.